Alan Hartman

target

Avexis

bidder

Novartis

£5,275m

60 dealmakers

target

Pharmacyclics Inc.

bidder

Abbvie

£13,661m

4 dealmakers

target

Receptos Inc.

bidder

Celgene Corporation

£4,639m

4 dealmakers

target

Anacor Pharmaceuticals Inc.

bidder

Pfizer

value n/a

1 dealmaker

target

Medivation Inc.

bidder

Pfizer

value n/a

3 dealmakers

target

Tesaro

bidder

Glaxosmithkline

£3,371m

41 dealmakers

target

Antelliq Group

bidder

Merck Animal Health

£2,922m

30 dealmakers

target

Consumer Health Joint Venture

bidder

Pfizer

£9,800m

78 dealmakers

target

Spark Therapeutics

bidder

Roche Holdings

£3,291m

29 dealmakers

target

Nightstar Therapeutics

bidder

Biogen

£663m

30 dealmakers

target

OMNICARE

bidder

Cvs Health Corporation

£8,181m

4 dealmakers

target

UPJOHN

bidder

Mylan

£18,106m

144 dealmakers

target

Merck & Co (women’s Health, Trusted Legacy Brands, And Biosimilars Businesses)

bidder

Institutional Investors

£5,390m

17 dealmakers

target

Forty Seven

bidder

Gilead Sciences

£3,821m

48 dealmakers

target

Principia Biopharma

bidder

Sanofi

£2,750m

35 dealmakers

target

IMMUNOMEDICS

bidder

Gilead Sciences

£16,407m

50 dealmakers

target

Gw Pharmaceuticals

bidder

Jazz Pharmaceuticals

£5,266m

85 dealmakers

target

Medline Industries

bidder

Hellman & Friedman

£24,007m

133 dealmakers

target

Translate Bio

bidder

Sanofi

£2,302m

52 dealmakers

target

Acceleron Pharma

bidder

Merck & Co

£8,528m

80 dealmakers

target

Seagen

bidder

Pfizer

£35,705m

67 dealmakers

target

Iveric Bio

bidder

Astellas Pharma

£4,693m

22 dealmakers

target

Mirati Therapeutics

bidder

Bristol Myers Squibb Company

£3,840m

54 dealmakers

target

Cerevel Therapeutics

bidder

Abbvie

£6,894m

57 dealmakers